These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 29103751)

  • 1. Cost-effectiveness of nivolumab for recurrent or metastatic head and neck cancer☆.
    Ward MC; Shah C; Adelstein DJ; Geiger JL; Miller JA; Koyfman SA; Singer ME
    Oral Oncol; 2017 Nov; 74():49-55. PubMed ID: 29103751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of nivolumab in the treatment of head and neck cancer.
    Hirschmann A; Lupatsch JE; Schwenkglenks M; Panje CM; Matter-Walstra K; Espeli V; Dedes KJ; Siano M;
    Oral Oncol; 2018 Dec; 87():104-110. PubMed ID: 30527224
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness of Nivolumab in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma.
    Zargar M; McFarlane T; Chan KKW; Wong WWL
    Oncologist; 2018 Feb; 23(2):225-233. PubMed ID: 29021380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness Analysis of Nivolumab for Treatment of Platinum-Resistant Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Tringale KR; Carroll KT; Zakeri K; Sacco AG; Barnachea L; Murphy JD
    J Natl Cancer Inst; 2018 May; 110(5):479-485. PubMed ID: 29126314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing.
    Matter-Walstra K; Schwenkglenks M; Aebi S; Dedes K; Diebold J; Pietrini M; Klingbiel D; von Moos R; Gautschi O;
    J Thorac Oncol; 2016 Nov; 11(11):1846-1855. PubMed ID: 27311996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Greenhalgh J; Bagust A; Boland A; Fleeman N; McLeod C; Dundar Y; Proudlove C; Shaw R
    Health Technol Assess; 2009 Oct; 13 Suppl 3():49-54. PubMed ID: 19846029
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab vs Pembrolizumab for Treatment of US Patients With Platinum-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Network Meta-analysis and Cost-effectiveness Analysis.
    Pei R; Shi Y; Lv S; Dai T; Zhang F; Liu S; Wu B
    JAMA Netw Open; 2021 May; 4(5):e218065. PubMed ID: 33956130
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
    N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis.
    Ye D; Liang X; Chen X; Li Y
    Sci Rep; 2024 Mar; 14(1):6807. PubMed ID: 38514766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nivolumab in recurrent/metastatic head and neck cancers.
    Karabajakian A; Reverdy T; Gau M; Fayette J
    Future Oncol; 2018 Mar; 14(7):603-609. PubMed ID: 29130342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
    Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
    J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic evaluation of nivolumab as a second-line treatment for advanced renal cell carcinoma from US and Chinese perspectives.
    Wan XM; Peng LB; Ma JA; Li YJ
    Cancer; 2017 Jul; 123(14):2634-2641. PubMed ID: 28301684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
    Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
    BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy.
    Kazandjian D; Suzman DL; Blumenthal G; Mushti S; He K; Libeg M; Keegan P; Pazdur R
    Oncologist; 2016 May; 21(5):634-42. PubMed ID: 26984449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors.
    Verma V; Sprave T; Haque W; Simone CB; Chang JY; Welsh JW; Thomas CR
    J Immunother Cancer; 2018 Nov; 6(1):128. PubMed ID: 30470252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.
    Ferris RL; Licitra L; Fayette J; Even C; Blumenschein G; Harrington KJ; Guigay J; Vokes EE; Saba NF; Haddad R; Ramkumar S; Russell J; Brossart P; Tahara M; Colevas AD; Concha-Benavente F; Lynch M; Li L; Gillison ML
    Clin Cancer Res; 2019 Sep; 25(17):5221-5230. PubMed ID: 31239321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
    Courtney PT; Yip AT; Cherry DR; Salans MA; Kumar A; Murphy JD
    JAMA Netw Open; 2021 May; 4(5):e218787. PubMed ID: 33938936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.